Boothbay Fund Management’s Amicus Therapeutics FOLD Stock Holding History

Boothbay Fund Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,472	Closed	-$412K	–	2371
2026 Q1	$412K	Sell	28,472 -205,185	-88%	-$2.94M	0.01%	1447
2025 Q4	$3.33M	Buy	+233,657	New	+$2.3M	0.05%	426
2024 Q4	–	Sell	-24,857	Closed	-$265K	–	1639
2024 Q3	$265K	Buy	+24,857	New	+$271K	0.01%	1304
2022 Q4	–	Sell	-13,553	Closed	-$141K	–	2138
2022 Q3	$141K	Buy	+13,553	New	+$151K	﹤0.01%	1956
2022 Q1	–	Sell	-16,530	Closed	-$191K	–	2357
2021 Q4	$191K	Sell	16,530 -42,562	-72%	-$474K	﹤0.01%	1506
2021 Q3	$564K	Buy	59,092 +304	+0.5%	+$3.11K	0.02%	1029
2021 Q2	$567K	Buy	58,788 +14,767	+34%	+$144K	0.02%	943
2021 Q1	$435K	Buy	+44,021	New	+$681K	0.02%	1009

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Boothbay Fund Management's FOLD Position: Q2 2026 in Review

Boothbay Fund Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 28,472 shares — an estimated $412K sold.

Boothbay Fund Management first reported a position in FOLD in Q1 2021 and held it in 8 quarters. The position peaked at $3.33M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Boothbay Fund Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 28,472 Amicus Therapeutics shares in Q2 2026, an estimated $412K.
Boothbay Fund Management first reported a position in Amicus Therapeutics in Q1 2021 and held it in 8 quarters.
Boothbay Fund Management's Amicus Therapeutics position peaked at $3.33M in Q4 2025.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.